Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
Recruiting · NCT05636514 · Registry updated 2026-03-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-03-18 | NCT05636514 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Australian National University | 7 |
| Clinical Hub for Interventional Research (CHOIR) | 4 |
| The University of New South Wales | 23 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Concord Repatriation and General Hospital | Sydney | Australia | 1 |
| Nepean Hospital | Sydney | Australia | 2 |
| Prince of Wales Hospital | Sydney | Australia | 12 |
| Royal Prince Alfred Hospital | Sydney | Australia | 19 |
| Westmead Hospital | Westmead | Australia | 128 |